Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation

BACKGROUND: When anti-VEGF (vascular endothelial growth factor) antibody bevacizumab is applied in neoadjuvant treatment of colorectal cancer patients with liver metastasis, 5–6 weeks between last bevacizumab dose and liver resection are currently recommended to avoid complications in wound and live...

Descripción completa

Detalles Bibliográficos
Autores principales: Starlinger, P, Alidzanovic, L, Schauer, D, Maier, T, Nemeth, C, Perisanidis, B, Tamandl, D, Gruenberger, B, Gruenberger, T, Brostjan, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464762/
https://www.ncbi.nlm.nih.gov/pubmed/22850548
http://dx.doi.org/10.1038/bjc.2012.342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464762/
https://www.ncbi.nlm.nih.gov/pubmed/22850548
http://dx.doi.org/10.1038/bjc.2012.342

Ejemplares similares